文章预览
各领域专家汇聚在BioSpark Monthly News论坛，交流过去一个月发生的 生物医药领域大事件 。 本月热点 TOPICS 1 . Oncology & Autoimmune Diseases： Roche discontinued two phase 3 NSCLC studies with anti-TIGIT after negative results from SKYSCRAPER-06; BioNTech & Regeneron reported positive phase 2 results for neoantigen vaccine BNT111 plus Libtayo in patients with R/R unresectable advanced melanoma; Revolution Medicines’ RAS(ON) multi-selective inhibitor RMC-6236 solidifies phase 3 plans with favorable safety profile and promising PFS data from a phase 1 trial of KRAS G12X PDAC patients; Eli Lilly acquired Morphic Therapeutic for $3.2B, focusing on oral integrin α4β7 inhibitor for inflammatory bowel disease; Allogeneic CD19-targeted CAR-T for patients with severe myositis and systemic sclerosis; 2 . New Modalities : Hengrui’s 2nd HER2-ADC entered ph2; Orum Therapeutics and Vertex signed collaboration agreement to develop novel Degrader-An
………………………………
